Zuckerberg San Francisco General Hospital
San Francisco, California, 94143, United States
Location contact
Armando Barraza, BA
CONTACT
Lisa Lawrence, BA
CONTACT
Neal Benowitz, MD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07829939
The goal of this clinical trial is to understand how using oral nicotine pouches effects the body in healthy volunteers. The main questions it aims to answer are:
1. With multiple use of oral nicotine pouches (ONPs) throughout the day, participants will adjust their intake of nicotine to be similar to or higher than that seen with cigarette smoking or vaping. 2. With multiple use of ONPs throughout the day, participants will experience satisfaction, psychological reward and relief of withdrawal symptoms similar to that seen with cigarette smoking or vaping. Participants will rate ONP use as a satisfactory substitute for cigarette smoking or vaping. 3. Examine the cardiovascular effects (blood pressure and heart rate) of placebo, 3mg and 6mg ONPs, and the participants' usual cigarette or e-cigarette (vape).
Participants will:
* use 3 different strengths of ONPs (0 mg, 3 mg, 6 mg) and their usual inhaled nicotine product (cigarette or e-cigarette/vape) * visit the hospital research ward on 4 separate days for 8 hours each day * use one of each of the products in a randomized order (by chance, like flipping a coin) on each of the 4 hospital study days
Trial opening soon.
Get Notified21 year–65 year
All sexes
Interventional
Phase 1
San Francisco, California, 94143, United States
Armando Barraza, BA
CONTACT
Lisa Lawrence, BA
CONTACT
Neal Benowitz, MD
PRINCIPAL_INVESTIGATOR
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
*Considered out of range if both machine and manual readings are above/below these thresholds.
Exclusion criteria
placebo
low strength oral nicotine pouches
high strength oral nicotine pouches
Participants will use their own cigarette or e-cigarette (vape)
Time frame: 7 hours post-dose
This will be assessed by comparing ratios of nicotine area under the plasma nicotine concentration time curve.
Time frame: Pre-dose until 7 hours post-dose.
This will be assessed by administering the Modified Cigarette Evaluation Questionnaire (mCEQ) throughout the day. The mCEQ uses three multi-item subscales and two single items: "Smoking Satisfaction" (items 1, 2, and 12); "Psychological Reward" (items 4 through 8); "Aversion" (items 9 and 10); "Enjoyment of Sensations" (item 3); and "Craving Reduction" (item 11). The items are rated on a seven-point scale ranging from 1 (not at all) to 7 (extremely). Scores for each subscale are calculated as the mean of the individual item responses or the single item. The minimum total score = 7 and maximum = 35 with higher scores indicating greater intensity on that scale.
Time frame: Pre-dose until 7 hours post-dose
The investigators will compare maximum change in heart rate as well as an integrated measure of heart rate after the first dose of nicotine over the following 7 hours among dosages.
Contact information is provided by the study sponsor or research team.
Armando Barraza, BA
CONTACT
Lisa Lawrence, BA
CONTACT
University of California, San Francisco
Other
Clinical Pharmacology of Oral Nicotine Pouches
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07827690
Acute Pain, Healthy Adult Participants
Indianapolis, Indiana, United States
View Trial DetailsNCT07473817
Healthy Adult Participants, Liver Disease Chronic
View Trial DetailsNCT07826910
Brain Diseases, Central Nervous System Diseases
Zurich, Canton of Zurich, Switzerland
View Trial DetailsNCT07820891
Healthy Adult Participants
View Trial Details